Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Hoffman Amnon


 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Itin C, Domb AJ, Hoffman A. On the Suitability of Porcine Labial Mucosa as a Model for Buccal Mucosal Drug Delivery Research. J Pharm Sci 2021;110(4):1863-1864.

(2) Itin C, Komargodski R, Barasch D, Domb AJ, Hoffman A. Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs. J Pharm Sci 2021;110(4):1824-1833.

(3) Gilon C, Gitlin-Domagalska A, Lahiani A, Yehoshua-Alshanski S, Shumacher-Klinger A, Gilon D, et al. Novel humanin analogs confer neuroprotection and myoprotection to neuronal and myoblast cell cultures exposed to ischemia-like and doxorubicin-induced cell death insults. Peptides 2020;134.

(4) Talhami A, Swed A, Hess S, Ovadia O, Greenberg S, Schumacher-Klinger A, et al. Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs. Front Chem 2020;8.

(5) Itin C, Komargodski R, Domb AJ, Hoffman A. Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study. J Pharm Sci 2020;109(9):2729-2734.

(6) Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Eur J Pharm Biopharm 2020;154:108-115.

(7) Izgelov D, Freidman M, Hoffman A. Investigation of cannabidiol gastro retentive tablets based on regional absorption of cannabinoids in rats. Eur J Pharm Biopharm 2020;152:229-235.

(8) Izgelov D, Regev A, Domb AJ, Hoffman A. Using the Absorption Cocktail Approach to Assess Differential Absorption Kinetics of Cannabidiol Administered in Lipid-Based Vehicles in Rats. Mol Pharm 2020;17(6):1979-1986.

(9) Izgelov D, Domb AJ, Hoffman A. The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration. Eur J Pharm Sci 2020;148.

(10) Itin C, Barasch D, Domb AJ, Hoffman A. Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. Int J Pharm 2020;581.

(11) Izgelov D, Shmoeli E, Domb AJ, Hoffman A. The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats. Int J Pharm 2020;580.

(12) Itin C, Domb AJ, Hoffman A. A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states. Expert Opin Drug Deliv 2019;16(10):1031-1035.

(13) Dishon S, Schumacher-Klinger A, Gilon C, Hoffman A, Nussbaum G. Myristoylation Confers Oral Bioavailability and Improves the Bioactivity of c(MyD 4-4), a Cyclic Peptide Inhibitor of MyD88. Mol Pharm 2019;16(4):1516-1522.

(14) Dishon S, Schumacher A, Fanous J, Talhami A, Kassis I, Karussis D, et al. Development of a novel backbone cyclic peptide inhibitor of the innate immune TLR/IL1R signaling protein MyD88. Sci Rep 2018;8(1).

(15) Räder AFB, Weinmüller M, Reichart F, Schumacher-Klinger A, Merzbach S, Gilon C, et al. Orally Active Peptides: Is There a Magic Bullet? Angew Chem Int Ed 2018;57(44):14414-14438.

(16) Schumacher-Klinger A, Fanous J, Merzbach S, Weinmüller M, Reichart F, Räder AFB, et al. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. Mol Pharm 2018;15(8):3468-3477.

(17) Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb AJ, Deutsch L, et al. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. J Pharm Sci 2018;107(5):1423-1429.

(18) Izgelov D, Cherniakov I, Aldouby Bier G, Domb AJ, Hoffman A. The Effect of Piperine Pro-Nano Lipospheres on Direct Intestinal Phase II Metabolism: The Raloxifene Paradigm of Enhanced Oral Bioavailability. Mol Pharm 2018;15(4):1548-1555.

(19) Weinmüller M, Rechenmacher F, Kiran Marelli U, Reichart F, Kapp TG, Räder AFB, et al. Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3. Angew Chem Int Ed 2017;56(51):16405-16409.

(20) Valitsky M, Hoffman A, Unterman T, Bar-Tana J. Insulin sensitizer prevents and ameliorates experimental type 1 diabetes. Am J Physiol Endocrinol Metab 2017;313(6):E672-E680.

(21) Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release 2017;266:1-7.

(22) Cherniakov I, Izgelov D, Domb AJ, Hoffman A. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci 2017;109:21-30.

(23) Fanous J, Swed A, Joubran S, Hurevich M, Britan-Rosich E, Kotler M, et al. Superiority of the S,S conformation in diverse pharmacological processes: Intestinal transport and entry inhibition activity of novel anti-HIV drug lead. Int J Pharm 2015;495(2):660-663.

(24) Marelli UK, Ovadia O, Frank AO, Chatterjee J, Gilon C, Hoffman A, et al. Cis-Peptide Bonds: A Key for Intestinal Permeability of Peptides? Chem Eur J 2015;21(43):15148-15152.

(25) Reich R, Hoffman A, Suresh RR, Shai O, Frant J, Maresca A, et al. Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo. J Enzyme Inhib Med Chem 2015;30(5):767-772.

(26) Cherniakov I, Domb AJ, Hoffman A. Self-nano-emulsifying drug delivery systems: An update of the biopharmaceutical aspects. Expert Opin Drug Deliv 2015;12(7):1121-1133.

(27) Levi I, Eskira Y, Eisenstein M, Gilon C, Hoffman A, Tal-Gan Y, et al. Corrigendum to Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: Molecular and behavioural aspects [Eur. Neuropsychopharmacol., 23, (2013), 1806-1815] Doi: 10.1016/j.euroneuro.2013.02.004. Eur Neuropsychopharmacol 2015;25(11):2185.

(28) Ickowicz DE, Farber S, Sionov E, Kagan S, Hoffman A, Polacheck I, et al. Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide. Biomacromolecules 2014;15(6):2079-2089.

(29) Haroutiunian S, Kagan L, Yifrach-Damari I, Davidson E, Ratz Y, Hoffman A. Enhanced antinociceptive efficacy of epidural compared with i.v. methadone in a rat model of thermal nociception. Br J Anaesth 2014;112(1):150-158.

(30) Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): The underlying mechanisms for amiodarone and talinolol. Pharm Res 2013;30(12):3029-3044.

(31) Burshtein G, Friedman M, Greenberg S, Hoffman A. Transepithelial transport of a natural cholinesterase inhibitor, huperzine a, along the gastrointestinal tract: The role of ionization on absorption mechanism. Planta Med 2013;79(3-4):259-265.

(32) Levi I, Eskira Y, Eisenstein M, Gilon C, Hoffman A, Talgan Y, et al. Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: Molecular and behavioral aspects. Eur Neuropsychopharmacol 2013;23(12):1806-1815.

(33) Reich R, Hoffman A, Veerendhar A, Maresca A, Innocenti A, Supuran CT, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment(1). J Med Chem 2012;55(17):7875-7882.

(34) Horwitz E, Shavit O, Shouval R, Hoffman A, Shapiro M, Moses AE. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions. Int J Clin Pharm 2012;34(4):611-617.

(35) Beck JG, Chatterjee J, Laufer B, Kiran MU, Frank AO, Neubauer S, et al. Intestinal permeability of cyclic peptides: Common key backbone motifs identified. J Am Chem Soc 2012;134(29):12125-12133.

(36) Avramoff A, Khan W, Ezra A, Elgart A, Hoffman A, Domb AJ. Cyclosporin pro-dispersion liposphere formulation. J Control Release 2012;160(2):401-406.

(37) Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chem Phys Lipids 2012;165(4):438-453.

(38) Horwitz E, Tal-Gan Y, Temper V, Shapiro M, Gilon C, Hoffman A. Chemical trapping of vancomycin: A potential strategy for preventing selection of vancomycin-resistant Enterococci. Microb Drug Resist 2012;18(2):109-115.

(39) Bollinger M, Manzenrieder F, Kolb R, Bochen A, Neubauer S, Marinelli L, et al. Tailoring of integrin ligands: Probing the charge capability of the metal ion-dependent adhesion site. J Med Chem 2012;55(2):871-882.

(40) Naveh S, Tal-Gan Y, Ling S, Hoffman A, Holoshitz J, Gilon C. Developing potent backbone cyclic peptides bearing the shared epitope sequence as rheumatoid arthritis drug-leads. Bioorg Med Chem Lett 2012;22(1):493-496.

(41) Gruzman A, Elgart A, Viskind O, Billauer H, Dotan S, Cohen G, et al. Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-diethyl dithioacetal in diabetic mice. J Cell Mol Med 2012;16(3):593-603.

(42) Horwitz E, Kagan L, Chamisha Y, Gati I, Hoffman A, Friedman M, et al. Novel gastroretentive controlled-release drug delivery system for amoxicillin therapy in veterinary medicine. J Vet Pharmacol Ther 2011;34(5):487-493.

(43) Horwitz E, Kagan L, Avni-Magen N, Daryi D, Gati I, Hoffman A, et al. A novel subcutaneous controlled-release amoxicillin degradable implant for extended-interval administration in veterinary medicine. J Vet Pharmacol Ther 2011;34(5):494-498.

(44) Frant J, Veerendhar A, Chernilovsky T, Nedvetzki S, Vaksman O, Hoffman A, et al. Orally Active, Antimetastatic, Nontoxic Diphenyl Ether-Derived Carbamoylphosphonate Matrix Metalloproteinase Inhibitors. ChemMedChem 2011;6(8):1471-1477.

(45) Kovo M, Wainstein J, Matas Z, Haroutiunian S, Hoffman A, Golan A. Erratum: Placental transfer of the insulin analog glargine in the ex vivo perfused placental cotyledon model (Endocrine Research 36: 1 (19-24)). Endocr Res 2011;36(2):91.

(46) Ovadia O, Greenberg S, Chatterjee J, Laufer B, Opperer F, Kessler H, et al. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm 2011;8(2):479-487.

(47) Kovo M, Golan A, Wainstein J, Matas Z, Haroutiunian S, Hoffman A. Placental transfer of the insulin analog glargine in the ex vivo perfused placental cotyledon model. Endocr Res 2011;36(1):19-24.

(48) Kagan L, Dreifinger T, Mager DE, Hoffman A. Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos 2010;38(9):1560-1566.

(49) Elgart A, Farber S, Domb AJ, Polacheck I, Hoffman A. Polysaccharide pharmacokinetics: Amphotericin B arabinogalactan conjugate-A drug delivery system or a new pharmaceutical entity? Biomacromolecules 2010;11(8):1972-1977.

(50) Hurevich M, Swed A, Joubran S, Cohen S, Freeman NS, Britan-Rosich E, et al. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: The HIV-1 CD4:gp120 paradigm. Bioorg Med Chem 2010;18(15):5754-5761.

(51) Ovadia O, Greenberg S, Laufer B, Gilon C, Hoffman A, Kessler H. Improvement of drug-like properties of peptides: The somatostatin paradigm. Expert Opin Drug Discov 2010;5(7):655-671.

(52) Ovadia O, Linde Y, Haskell-Luevano C, Dirain ML, Sheynis T, Jelinek R, et al. The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: The melanocortin agonist paradigm. Bioorg Med Chem 2010;18(2):580-589.

(53) Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone. J Pharm Sci 2010;99(6):2739-2749.

(54) Swed A, Eyal S, Madar I, Zohar-Kontante H, Weiss L, Hoffman A. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium. Mol Pharm 2009;6(6):1883-1890.

(55) Haroutiunian S, Lecht S, Zur AA, Hoffman A, Davidson E. The challenge of pain management in patients with myasthenia gravis. J Pain Palliative Care Pharmacother 2009;23(3):242-260.

(56) Haroutiunian S, Rabinovich B, Adam M, Hoffman A, Ratz Y. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: A retrospective study. J Clin Pharmacol 2009;49(11):1363-1369.

(57) Chatterjee J, Ovadia O, Gilon C, Hoffman A, Mierke D, Kessler H. N-methylated cyclic pentapeptides as template structures. Adv Exp Med Biol 2009;611:109-110.

(58) Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, et al. Highly selective cyclic hexapeptides antagonist of GPIIb-IIIa by multiple N-Methylation. Adv Exp Med Biol 2009;611:209-210.

(59) Kagan L, Lavy E, Hoffman A. Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm Pharmacol Ther 2009;22(3):260-265.

(60) Kagan L, Hoffman A. Biopharmaceutical aspects of gastro-retentive dosage forms: The gabapentin paradigm. J Drug Deliv Sci Technol 2009;19(4):233-239.

(61) Gershkovich P, Itin C, Yacovan A, Amselem S, Hoffman A. Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. Transl Res 2009;153(6):296-300.

(62) Gershkovich P, Fanous J, Qadri B, Yacovan A, Amselem S, Hoffman A. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: In-silico prediction of uptake by chylomicrons. J Pharm Pharmacol 2009;61(1):31-39.

(63) Ginosar Y, Nadjari M, Hoffman A, Firman N, Davidson EM, Weiniger CF, et al. Antepartum continuous epidural ropivacaine therapy reduces uterine artery vascular resistance in pre-eclampsia: A randomized, dose-ranging, placebo-controlled study. Br J Anaesth 2009;102(3):369-378.

(64) Gruzman A, Shamni O, Yakir MB, Sandovski D, Elgart A, Alpert E, et al. Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase α. J Med Chem 2008;51(24):8096-8108.

(65) Linde Y, Ovadia O, Safrai E, Xiang Z, Portillo FP, Shalev DE, et al. Structure-activity relationship and metabolic stability studies of Backbone cyclization and N-methylation of melanocortin peptides. Biopolym Pept Sci Sect 2008;90(5):671-682.

(66) Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: A new perspective in medicinal chemistry. Acc Chem Res 2008;41(10):1331-1342.

(67) Mansur N, Weiss A, Hoffman A, Gruenewald T, Beloosesky Y. Continuity and adherence to long-term drug treatment by geriatric patients after hospital discharge: A prospective cohort study. Drugs Aging 2008;25(10):861-870.

(68) Shavit O, Leshno M, Goldberger A, Shmueli A, Hoffman A. The authors' reply. Pharmacoeconomics 2008;26(10):892-894.

(69) Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor - Synthesis and pharmacodynamic and pharmacokinetic analysis (Journal of Medicinal Chemistry (2008) 51, (1408)). J Med Chem 2008;51(14):4357-4358.

(70) Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008;129(1):1-10.

(71) Kagan L, Hoffman A. Systems for region selective drug delivery in the gastrointestinal tract: Biopharmaceutical considerations. Expert Opin Drug Deliv 2008;5(6):681-692.

(72) Hoffman A, Qadri B. Eligen insulin - A system for the oral delivery of insulin for diabetes. IDrugs 2008;11(6):433-441.

(73) Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, Hoffman A. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat Diagn 2008;28(6):544-548.

(74) Kagan L, Hoffman A. Selection of drug candidates for gastroretentive dosage forms: Pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm 2008;69(1):238-246.

(75) Biron E, Chatterjee J, Ovadia O, Langenegger D, Brueggen J, Hoyer D, et al. Improving oral bioavailability of peptides by multiple N-methylation: Somatostatin analogues. Angew Chem Int Ed 2008;47(14):2595-2599.

(76) Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor-synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem 2008;51(5):1406-1414.

(77) Hoffman A, Horwitz E, Hess S, Cohen-Poradosu R, Kleinberg L, Edelberg A, et al. Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials. Pharm Res 2008;25(3):667-671.

(78) Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem 2008;51(4):1026-1034.

(79) Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release 2008;126(1):1-9.

(80) Kovo M, Haroutiunian S, Feldman N, Hoffman A, Glezerman M. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol 2008;136(1):29-33.

(81) Dahan A, Mendelman A, Amsili S, Ezov N, Hoffman A. The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: Comparison between anesthetized and freely moving conscious rat models. Eur J Pharm Sci 2007;32(4-5):367-374.

(82) Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, et al. Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem 2007;50(24):5878-5881.

(83) Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, et al. Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem 2007;50(24):6201-6211.

(84) Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm 2007;67(3):759-765.

(85) Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: The importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci 2007;32(1):24-32.

(86) Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline - A novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manage 2007;3(3):467-474.

(87) Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm 2007;67(1):96-105.

(88) Gershkovich P, Qadri B, Yacovan A, Amselem S, Hoffman A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: Dexanabinol and PRS-211,220. Eur J Pharm Sci 2007;31(5):298-305.

(89) Szalat A, Gershkovich P, Ben-Ari A, Shaish A, Liberman Y, Boutboul E, et al. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim Biophys Acta Mol Cell Biol Lipids 2007;1771(7):839-844.

(90) Dvir E, Elman A, Simmons D, Shapiro I, Duvdevani R, Dahan A, et al. DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. CNS Drug Rev 2007;13(2):260-277.

(91) Dahan A, Duvdevani R, Dvir E, Elmann A, Hoffman A. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J Control Release 2007;119(1):86-93.

(92) Gershkovich P, Shtainer D, Hoffman A. The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. Int J Pharm 2007;333(1-2):1-4.

(93) Dahan A, Hoffman A. Mode of administration-dependent brain uptake of indomethacin: Sustained systemic input increases brain influx. Drug Metab Dispos 2007;35(2):321-324.

(94) Shavit O, Leshno M, Goldberger A, Shmueli A, Hoffman A. It's time to choose the study design! Net benefit analysis of alternative study designs to acquire information for evaluation of health technologies. Pharmacoeconomics 2007;25(11):903-911.

(95) Dvir E, Friedman JE, Lee JY, Koh JY, Younis F, Raz S, et al. Erratum: A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3- indolyl acetamido]butanoyl}-sn-glycero-3-phosophatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid β in an Alzheimer's disease model (Journal of Pharmacology and Experimental Therapies (2006) 318 (1248-1256)). J Pharmacol Exp Ther 2006;319(3):1492.

(96) Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res 2006;23(9):2165-2174.

(97) Dvir E, Friedman JE, Lee JY, Koh JY, Younis F, Raz S, et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]butanoyl}-sn-glycero-3-phosophatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid β in an Alzheimer's disease model. J Pharmacol Exp Ther 2006;318(3):1248-1256.

(98) Kagan L, Lapidot N, Afargan M, Kirmayer D, Moor E, Mardor Y, et al. Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans. J Control Release 2006;113(3):208-215.

(99) Fourcroy JL, Hoffman A. Prolonged-release ciprofloxacin. Am J Drug Deliv 2006;4(2):121.

(100) Bercovich D, Friedlander Y, Korem S, Houminer A, Hoffman A, Kleinberg L, et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 2006;185(1):97-107.

(101) Dahan A, Hoffman A. Enhanced gastrointestinal absorption of lipophilic drugs. Enhancement in Drug Delivery; 2006. p. 111-131.

(102) Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: Linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 2005;26(5):394-404.

(103) Perlstein I, Burton DY, Ryan K, DeFelice S, Simmers E, Campbell B, et al. Posttranslational control of a cardiac ion channel transgene in vivo: Clarithromycin-hMiRP1-Q9E interactions. Hum Gene Ther 2005;16(7):906-910.

(104) Hess S, Rotshild V, Hoffman A. Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl) amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Eur J Pharm Sci 2005;25(2-3):307-312.

(105) Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci 2005;24(4):381-388.

(106) Falk R, Grunwald J, Hoffman A, Domb AJ, Polacheck I. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Antimicrob Agents Chemother 2004;48(9):3606-3609.

(107) Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004;277(1-2):141-153.

(108) Klausner EA, Lavy E, Barta M, Cserepes E, Friedman M, Hoffman A. Novel gastroretentive dosage forms: Evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res 2003;20(9):1466-1473.

(109) Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: Models for uptake and release of drugs. Clin Pharmacokinet 2003;42(10):863-881.

(110) Klausner EA, Lavy E, Stepensky D, Cserepes E, Barta M, Friedman M, et al. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J Clin Pharmacol 2003;43(7):711-720.

(111) Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003;90(2):143-162.

(112) Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel levodopa gastroretentive dosage form: In-vivo evaluation in dogs. J Control Release 2003;88(1):117-126.

(113) Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage forms: Evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res 2002;19(10):1516-1523.

(114) Mayan H, Bloom E, Hoffman A. Use of digoxin monitoring in a hospital setting as an essential tool in optimizing therapy. J Pharm Technol 2002;18(3):133-136.

(115) Stepensky D, Golomb G, Hoffman A. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci 2002;91(2):508-516.

(116) Perlstein I, Stepensky D, Krzyzanski W, Hoffman A. A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. J Pharm Sci 2002;91(12):2500-2510.

(117) Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 2002;30(8):861-868.

(118) Perlstein I, Sapir N, Backon J, Sapoznikov D, Karasik R, Havlin S, et al. Scaling vs. nonscaling methods of assessing autonomic tone in streptozotocin-induced diabetic rats. Am J Physiol Heart Circ Physiol 2002;283(3 52-3):H1142-H1149.

(119) Hoffman A, Stepensky D, Ezra A, Van Gelder JM, Golomb G. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm 2001;220(1-2):1-11.

(120) Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Release 2001;71(1):107-115.

(121) Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, et al. Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin. Endocrinology 2001;142(1):477-486.

(122) The cumulative plot of power spectral analysis of heart rate variability assesses the kinetics of action of cholinergic drugs in rats. Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings; 2000.

(123) Ezra A, Hoffman A, Breuer E, Alferiev IS, Mönkkönen J, El Hanany-Rozen N, et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem 2000;43(20):3641-3652.

(124) Shani S, Morginstin T, Hoffman A. Patients' perceptions of drug therapy counseling in Israel. Isr Med Assoc J 2000;2(6):438-441.

(125) Lomnicky Y, Haimov T, Luria MH, Friedman M, Hoffman A. Pharmacodynamic effects of bezafibrate and niacin combination: Implications of the mode of administration. J Pharm Sci 2000;89(8):1046-1053.

(126) Cohen H, Alferiev IS, Mönkkönen J, Seibel MJ, Pinto T, Ezra A, et al. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharm Res 1999;16(9):1399-1406.

(127) Hoffman A, Lomnicky Y, Luria MH, Gilhar D, Friedman M. Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: Pharmacodynamic rationale for sustained release preparation of the drug. Pharm Res 1999;16(7):1093-1097.

(128) Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999;16(6):571-639.

(129) Hoffman A, Perlstein I, Habib G, Pinto E, Gilhar D. The effect of cimetidine on the pharmacodynamics of theophylline-induced seizures and ethanol hypnotic activity. Pharmacol Toxicol 1999;85(5):130-132.

(130) Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev 1998;33(3):185-199.

(131) Hoffman A, Danenberg HD, Katzhendler I, Shuval R, Gilhar D, Friedman M. Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form. J Control Release 1998;54(1):29-37.

(132) Hoffman A. Preface. Adv Drug Deliv Rev 1998;33(3):183-184.

(133) Ezra A, Hoffman A, Breuer E, Weiss G, Golomb G. Proteins: Carrier-mediated absorption of bisphosphonate prodrugs. Proc Control Release Soc 1998(25):473-474.

(134) Lomnicky Y, Friedman M, Luria MH, Raz I, Hoffman A. The effect of the mode of administration on the hypolipidaemic activity of niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats. J Pharm Pharmacol 1998;50(11):1233-1239.

(135) Sevransky JE, Shaked G, Novogrodsky A, Levitzki A, Gazit A, Hoffman A, et al. Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J Clin Invest 1997;99(8):1966-1973.

(136) Hoffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 1997;33(4):285-301.

(137) Katzhendler I, Hoffman A, Friedman M. Drug release mechanism from hydrophilic matrix tablets. PROC CONTROL RELEASE SOC 1997(24):441-442.

(138) Hoffman A, Afargan M, Backon J, Perlstein I. The anticonvulsant effect of deprenyl on pentylenetetrazol-induced seizures in lewis rats. Int J Neurosci 1997;90(3-4):223-232.

(139) Katzhendler I, Hoffman A, Goldberger A, Friedman M. Modeling of Drug Release from Erodible Tablets. J Pharm Sci 1997;86(1):110-115.

(140) Ezra A, Hoffman A, Breuer E, Weiss G, Lipka E, Amidon GL, et al. Peptidyl prodrugs for improved oral absorption. PROC CONTROL RELEASE SOC 1997(24):243-244.

(141) Ezra A, Breuer E, Amidon G, Hoffman A, Ornoy A, Patlas N, et al. Peptidyl prodrug of bisphosphonates for improved oral absorption. PROC CONTROL RELEASE SOC 1996(23):83-84.

(142) Golomb G, Van Gelder JM, Alferiev IS, Ornoy A, Hoffman A, Schlossman A, et al. Novel bisphosphonates for calcium-related disorders. Phosphorus Sulfur Silicon Relat Elem 1996;109(1-4):221-224.

(143) Golomb G, Shaked I, Hoffman A. Intrauterine administration of peptide drugs for systemic effect. Adv Drug Deliv Rev 1995;17(2):179-190.

(144) Hoffman A, Shouval R, Katzhendler I, Gilhar D, Friedman M. Pharmacodynamic rationale for controlled-release beta lactam antibiotics: A new controlled release dosage form of amoxicillin. PROC CONTROL RELEASE SOC 1995(22):210-211.

(145) Donbrow M, Hoffman A, Benita S. Gradation of microcapsule wall porosity by deposition of polymer mixtures (eudragit RL and eudragit RS). Phase separation of polymer mixtures and effects of external media and conditions on release. J Microencapsulation 1995;12(3):273-285.

(146) Hoffman A, Shaked I, Nyska A, Avramoff A, Golomb G. Trans-endometrial route of drug administration: In-vitro and in-vivo evaluation. PROC CONTROL RELEASE SOC 1995(22):568-569.

(147) Hoffman A, Goldberg A. The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: Pharmacodynamic implications. J Pharmacokinet Biopharm 1994;22(6):449-468.

(148) Hoffman A, Nyska A, Avramoff A, Golomb G. Continuous versus pulsatile administration of erythropoietin (EPO) via the uterus in anemic rats. Int J Pharm 1994;111(2):197-202.

(149) Hoffman A, Fischer Y, Gilhar D, Raz I. The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus. Eur J Clin Pharmacol 1994;47(1):53-55.

(150) Hoffman A, Habib G. Valproic acid intensifies the depressant action of phenobarbital and ethanol by a pharmacodynamic medhanism. J Pharm Sci 1994;83(5):733-735.

(151) Raz I, Gilhar D, Hoffman A. Prolonged response to glibenclamide in NIDDM patients in a normoglycemic state. Isr J Med Sci 1994;30(10):775-778.

(152) KLANG SH, FRUCHT‐PERY J, HOFFMAN A, BENITA S. Physicochemical Characterization and Acute Toxicity Evaluation of a Positively‐charged Submicron Emulsion Vehicle. J Pharm Pharmacol 1994;46(12):986-993.

(153) Hoffman A, Pinto E, Afargan M, Schattner A. Cyclosporine enhances theophylline neurotoxicity in rats. J Pharm Sci 1994;83(4):559-561.

(154) Hoffman A, Alfon J, Siegal T, Siegal T. Pharmacodynamics of Phenobarbital Anesthesia and Pentylenetetrazol-Induced Maximal Seizures in a Rat Model of Neoplastic Spinal Cord Compression. Pharm Res 1994;11(4):536-540.

(155) HOFFMAN A, HABIB G, GILHAR D, ZOHAR H. Cyclosporin Increases the CNS Sensitivity to the Hypnotic Effect of Phenobarbitone but not Ethanol in Rats. J Pharm Pharmacol 1994;46(9):760-764.

(156) Hoffman A, Alfon J, Habib G, Pinto E, Gorodetsky R. The Effect of Immunosuppression by Total-Body Irradiation on the Pharmacodynamics of Centrally Active Drugs in Rats. Pharm Res 1994;11(5):704-708.

(157) Hoffman A, Afargan M, Pinto E, Gilhar D, Backon J. Differential effects of various antiinflammatory drugs on theophylline neurotoxicity. Pharmacol Biochem Behav 1994;49(2):335-339.

(158) Golomb G, Niska A, Avramoff A, Shaked I, Hoffman A. Intrauterine controlled delivery of peptides for systemic effect. PROC CONTROL RELEASE SOC 1994(21):38-39.

(159) Hoffman A, Levy G. Kinetics of drug action in disease states. XLI. Effect of adrenalectomy on the hypnotic activity of phenobarbital, the neurotoxicity of theophylline and pain sensitivity in rats. J Pharmacol Exp Ther 1993;264(2):859-862.

(160) Breuer E, Golomb G, Hoffman A, Schlossman A, Van Gelder JM, Saadeh H, et al. In Vitro and In Vivo Inhibition of Hydroxyapatite Formation and Dissolution by Bisacylphosphonates and Bishydroxyiminophosphonates. Phosphorus Sulfur Silicon Relat Elem 1993;76(1-4):167-170.

(161) Hoffman A. Chronopharmacodynamics of theophylline neurotoxicity in rats. J Pharm Sci 1993;82(6):668-669.

(162) Hoffman A, Baluom M. Effect of acute experimental liver dysfunction on the pharmacodynamics of heptabarbital in rats. Acta Anaesthesiol Scand 1993;37(1):102-104.

(163) Hoffman A, Pinto E, Gilhar D. Effect of pretreatment with anticonvulsants on theophylline-induced seizures in the rat. J Crit Care 1993;8(4):198-202.

(164) Hoffman A, Klockowski PM, Levy G. Kinetics of drug action in disease states. XLII. Effect of repeated blood sampling on the pharmacodynamics of phenobarbital in rats. J Pharm Sci 1993;82(2):229-230.

(165) Golomb G, Avramoff A, Hoffman A. A New Route of Drug Administration: Intrauterine Delivery of Insulin and Calcitonin. Pharm Res 1993;10(6):828-833.

(166) Hoffman A. Potential pharmacodynamic effect of charcoal on theophylline neurotoxicity in normal rats. Pharmacol Biochem Behav 1992;43(2):621-623.

(167) Hoffman A, Alfon J. High-Dose Methotrexate Does Not Affect the Pharmacodynamics of Phenobarbital Hypnotic Action but Decreases the Central Nervous System (CNS) Sensitivity to Pentylenetetrazol-Induced Maximal Seizures in Rats. Pharm Res 1992;9(10):1295-1298.

(168) Golomb G, Eitan Y, Hoffman A. Measurement of Serum [3H]Tetracycline Kinetics and Indices of Kidney Function Facilitate Study of the Activity and Toxic Effects of Bisphosphonates in Bone Resorption. Pharm Res 1992;9(8):1018-1023.

(169) Hoffman A, Levy G. Kinetics of drug action in disease states. XL. Effect of the dialyzable component(s) of uremic blood on theophylline neurotoxicity in rats. Pharm Res 1991;8(3):415-417.

(170) Hoffman A, Levy G. Kinetics of Drug Action in Disease States. XXXIX. Effect of Orally Administered Activated Charcoal on the Hypnotic Activity of Phenobarbital and the Neurotoxicity of Theophylline Administered Intravenously to Rats with Renal Failure. Pharm Res 1990;7(3):242-246.

(171) Hoffman A, Levy G. Kinetics of drug action in disease states. XXXVI: Effect of cyclosporine on the pharmacodynamics and pharmacokinetics of a barbiturate (heptabarbital) in rats. J Pharm Sci 1990;79(1):19-22.

(172) Donbrow M, Hoffman A, Benita S. Phase separation modulation and aggregation prevention: Mechanism of the non-solvent addition method in the presence and absence of polyisobutylene as an additive. J Microencapsulation 1990;7(1):1-15.

(173) Hoffman A, Levy G. Gender Differences in the Pharmacodynamics of Barbiturates in Rats. Pharm Res 1989;6(11):976-981.

(174) Hoffman A, Levy G. Effect of enoxacin on theophylline neurotoxicity. Life Sci 1989;44(23):1803-1806.

(175) Hoffman A, Levy G. Kinetics of drug action in disease states. XXIX. Effects of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: Implications of severe hypoalbuminemia. J Pharmacol Exp Ther 1989;249(1):117-122.

(176) Babay D, Hoffman A, Benita S. Design and release kinetic pattern evaluation of indomethacin microspheres intended for oral administration. Biomaterials 1988;9(6):482-488.

(177) Donbrow M, Hoffman A, Benita S. Variation of Population Release Kinetics in Polydisperse Multiparticulate Systems (Microcapsules, Microspheres, Droplets, Cells) with Heterogeneity of One, Two or Three Parameters in the Population of Individuals. J Pharm Pharmacol 1988;40(2):93-96.

(178) Benita S, Babay D, Hoffman A, Donbrow M. Relation Between Individual and Ensemble Release Kinetics of Indomethacin from Microspheres. Pharm Res 1988;5(3):178-182.

(179) Hoffman A, Donbrow M, Benita S. Direct measurements on individual microcapsule dissolution as a tool for determination of release mechanism. J Pharm Pharmacol 1986;38(10):764-766.

(180) Gross ST, Hoffman A, Donbrow M, Benita S. Fundamentals of release mechanism interpretation in multiparticulate systems: the prediction of the commonly observed release equations from statistical population models for particle ensembles. Int J Pharm 1986;29(2-3):213-222.

(181) Hoffman A, Donbrow M, Gross ST, Benita S, Bahat R. Fundamentals of release mechanism interpretation in multiparticulate systems: determination of substrate release from single microcapsules and relation between individual and ensemble release kinetics. Int J Pharm 1986;29(2-3):195-211.

(182) Benita S, Hoffman A, Donbrow M. Polyacrylate resin (eudragit retard) microcapsules as a controlled release drug delivery system improved non-solvent addition phase separation process. J Microencapsulation 1985;2(3):207-222.

(183) BENITA S, HOFFMAN A, DONBROW M. Microencapsulation of paracetamol using polyacrylate resins (Eudragit Retard), kinetics of drug release and evaluation of kinetic model. J Pharm Pharmacol 1985;37(6):391-395.

(184) Donbrow M, Benita S, Hoffman A. Microencapsulation of dichromate and paracetamol with Eudragit Retard polymers using phase separation by nonsolvent addition. Appl Biochem Biotechnol 1984;10(1-3):245-249.